Engineered immune cells take aim at Hard-to-Treat prostate cancer

NCT ID NCT02744287

Terminated Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). The main goals were to check safety and find the right dose. The study was terminated early, but results help guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Baylor Sammons Cancer Center

Dallas, Texas, 75246, United States
Columbia University Medical Center

New York, New York, 10032, United States
Duke University

Durham, North Carolina, 27705, United States
Emory Winship Cancer Institute

Atlanta, Georgia, 30322, United States
John Theurer Cancer Center, Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Chicago Medicine

Chicago, Illinois, 60637, United States
University of Nebraska

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.